Latest News

  • Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results Read More
  • Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder Read More
  • Alkermes Receives Refusal to File Letter From FDA for ALKS 5461 Read More

Investors

Working at Alkermes